Israeli startup OncoHost announced today an upsized and oversubscribed $35 million Series C funding round, led by ALIVE Israel HealthTech VC, with the participation of Leumi Partners, Menora Mivtachim, OurCrowd and other existing investors. Clinical trial results have shown OncoHost's AI-powered precision oncology platform to have remarkably high accuracy in assessing non-small cell lung cancer (NSCLC) patient response at three months, six months and one year. Through one blood test pre-treatment, the company's multi-patented platform also provides clinicians with potential combination strategies to overcome treatment resistance. Last year, OncoHost CEO Dr. Ofer Sharon told me that "For immunotherapy, the most important treatment modality we have today, the response rate on average across all cancer types is about 20%. With all the promise of immunotherapy, if you have ten patients waiting in your waiting room with advanced cancer, only two will be alive in two years."